Dashboard
Manage Tickers

INABIN8BIO, INC.

Nasdaq in8bio.com


$ 1.03 $ 0.00 (0 %)    

Tuesday, 07-May-2024 12:30:18 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 441.71 $ 1.04 (0.24 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.14 $ -0.51 (-0.56 %)
GLD $ 218.73 $ 1.76 (0.81 %)
$ 1.01
$ 1.02
$ 0.00 x 0
$ 0.00 x 0
$ 1.02 - $ 1.03
$ 0.65 - $ 3.48
107,732
na
43.72M
$ 1.20
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-14-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-12-2023 03-31-2023 10-Q
6 03-30-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-12-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-17-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 09-10-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

in8bio-q1-2024-gaap-eps-020-misses-018-estimate
IN8bio Q1 2024 GAAP EPS $(0.20) Misses $(0...
05/09/2024 20:26:03

IN8bio (NASDAQ:INAB) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.18) by 1...

in8bio-doses-first-patient-in-phase-2-clinical-trial-of-inb-400-in-newly-diagnosed-glioblastoma
IN8bio Doses First Patient In Phase 2 Clin...
04/30/2024 10:07:17

12-health-care-stocks-moving-in-fridays-after-market-session
12 Health Care Stocks Moving In Friday's A...
04/12/2024 20:31:04

hc-wainwright--co-reiterates-buy-on-in8bio-maintains-14-price-target
HC Wainwright & Co. Reiterates Buy on IN8b...
04/10/2024 14:51:57

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates IN8bio (NASDAQ:INAB) with a Buy and maintains $14 price ta...

kill-leukemia-cells-while-preserving-healthy-tissues-nano-cap-cancer-focused-firm-in8bios-preclinical-candidate-shows-potential
Kill Leukemia Cells While Preserving Healt...
04/10/2024 14:38:13

IN8bio's nsCAR platform, INB-300. Presented at AACR 2024, new preclinical data highlights its superior selectivity in targe...

why-pricesmart-shares-are-trading-higher-by-around-5-here-are-20-stocks-moving-premarket
Why PriceSmart Shares Are Trading Higher B...
04/10/2024 12:12:43

Shares of PriceSmart, Inc. (NASDAQ: PSMT) rose sharply in today’s pre-market trading as the company posted better-than-expecte...

12-health-care-stocks-moving-in-wednesdays-pre-market-session
12 Health Care Stocks Moving In Wednesday'...
04/10/2024 12:09:34

in8bio-shares-are-trading-higher-after-the-company-announced-new-preclinical-data-for-inb-300
IN8bio shares are trading higher after the...
04/10/2024 11:26:24

in8bio-announces-presentation-of-new-preclinical-data-for-gamma-delta-nscar-t-cell-therapy-platform-at-aacr-2024-says-preclinical-data-supports-potential-for-proprietary-nscar-platform-to-selectively-eliminate-cancer-cells-while-preserving-healthy-tissue
IN8bio Announces Presentation Of New Precl...
04/09/2024 20:31:35

laidlaw--co-initiates-coverage-on-in8bio-with-buy-rating-announces-price-target-of-75
Laidlaw & Co. Initiates Coverage On IN8bio...
03/18/2024 11:35:12

Laidlaw & Co. analyst Yale Jen initiates coverage on IN8bio (NASDAQ:INAB) with a Buy rating and announces Price Target o...

hc-wainwright--co-reiterates-buy-on-in8bio-maintains-14-price-target
HC Wainwright & Co. Reiterates Buy on IN8b...
03/15/2024 10:09:49

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates IN8bio (NASDAQ:INAB) with a Buy and maintains $14 price ta...

in8bio-q4-eps-022-misses-014-estimate
IN8bio Q4 EPS $(0.22) Misses $(0.14) Estimate
03/14/2024 20:01:32

IN8bio (NASDAQ:INAB) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.14) by 5...

jonestrading-initiates-coverage-on-in8bio-with-buy-rating-announces-price-target-of-5
JonesTrading Initiates Coverage On IN8bio ...
03/13/2024 08:50:11

JonesTrading analyst Soumit Roy initiates coverage on IN8bio (NASDAQ:INAB) with a Buy rating and announces Price Target of $5.

in8bio-to-present-new-preclinical-data-on-novel-gamma-delta-car-platform-candidate-at-aacr-annual-meeting-2024
IN8bio To Present New Preclinical Data On ...
03/05/2024 21:32:14

New preclinical data demonstrating proof-of-concept for the non-signaling gamma-delta T cell CAR (nsCAR) platform candidate tar...

in8bio-announces-publication-on-novel-gamma-delta-t-cell-therapy-for-glioblastoma-in-frontiers-in-immunology
IN8bio Announces Publication On Novel Gamm...
02/14/2024 13:17:05

IN8bio, Inc. (NASDAQ:INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapi...

in8bio-highlights-recent-company-accomplishments-and-outlines-2024-pipeline-goals
IN8bio Highlights Recent Company Accomplis...
01/04/2024 13:30:58

Presented positive data showing continued durable complete remissions (CR) achieved in 100% of evaluable leukemia patients in P...

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
12/18/2023 21:31:50

12-health-care-stocks-moving-in-fridays-intraday-session
12 Health Care Stocks Moving In Friday's I...
12/15/2023 17:31:25

aigh-capital-management-reported-94-stake-in--in8bio-in-13g-filing
AIGH Capital Management Reported 9.4% Stak...
12/15/2023 11:33:34

why-despegarcom-shares-are-trading-higher-by-over-16-here-are-other-stocks-moving-in-wednesdays-mid-day-session
Why Despegar.com Shares Are Trading Higher...
12/13/2023 18:40:34

Shares of Despegar.com, Corp. (NYSE: DESP) rose sharply during Wednesday’s session after the company raised its FY23 financial ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION